Trial · NCT03729869

Impact of Progesterone on Stress Reactivity and Cannabis Use

NCT03729869, Phase 2, Completed, Medical University of South Carolina; results first posted 2023-09-28

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Impact of Progesterone on Stress Reactivity and Cannabis Use. Trials, record NCT03729869. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03729869

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Impact of Progesterone on Stress Reactivity and Cannabis Use
NCT number: NCT03729869
Status: Completed
Phases: Phase 2
Enrollment: 148 participants, actual
Lead sponsor: Medical University of South Carolina
Conditions: Cannabis Use
Interventions: Progesterone, Placebo
First posted: 2018-11-05
Last updated: 2023-09-28
Results first posted: 2023-09-28

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Cannabis Craving	Immediately post stress/cue task.	Subjects will rate marijuana craving on a 0-7 Likert scale where 0 is Not at All and 7 is extremely.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Cannabis Craving	Immediately post stress/cue task.	Males and females randomly assigned to take progesterone or placebo.	units on a scale	MEAN

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Cannabis Craving	Progesterone Males	3.7	Standard Deviation 2.3	units on a scale
Cannabis Craving	Placebo Males	3.4	Standard Deviation 2.2	units on a scale
Cannabis Craving	Progesterone Female	4.3	Standard Deviation 2.6	units on a scale
Cannabis Craving	Placebo Females	4.5	Standard Deviation 2.1	units on a scale

Source ClinicalTrials.gov

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Progesterone Males	40
Overall Study	STARTED	Placebo Males	42
Overall Study	STARTED	Progesterone Female	35
Overall Study	STARTED	Placebo Females	31
Overall Study	COMPLETED	Progesterone Males	39
Overall Study	COMPLETED	Placebo Males	41
Overall Study	COMPLETED	Progesterone Female	35
Overall Study	COMPLETED	Placebo Females	31
Overall Study	NOT COMPLETED	Progesterone Males	1
Overall Study	NOT COMPLETED	Placebo Males	1

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events92

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Headache	Nervous system disorders	Progesterone Males	9	39	9
other	Headache	Nervous system disorders	Placebo Males	7	41	7
other	Headache	Nervous system disorders	Progesterone Female	9	35	9
other	Headache	Nervous system disorders	Placebo Females	11	31	11
other	Marijuana withdrawal syndrome	General disorders	Progesterone Males	3	39	3
other	Marijuana withdrawal syndrome	General disorders	Placebo Males	8	41	8
other	Marijuana withdrawal syndrome	General disorders	Progesterone Female	1	35	1
other	Marijuana withdrawal syndrome	General disorders	Placebo Females	2	31	2
other	Irritability	Psychiatric disorders	Progesterone Males	6	39	6
other	Irritability	Psychiatric disorders	Placebo Males	4	41	4

1 to 10 of 92Source ClinicalTrials.gov

See all 92 adverse events

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Progesterone Males	0	39
Total, all-cause mortality	Placebo Males	0	41
Total, all-cause mortality	Progesterone Female	0	35
Total, all-cause mortality	Placebo Females	0	31
Total, other adverse events	Progesterone Males	26	39
Total, other adverse events	Placebo Males	28	41
Total, other adverse events	Progesterone Female	24	35
Total, other adverse events	Placebo Females	23	31
Total, serious adverse events	Progesterone Males	0	39
Total, serious adverse events	Placebo Males	0	41

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
U54DA016511	MUSC Specialized Center of Research Excellence on Sex Differences Renewal 2022	MCRAE-CLARK, AIMEE L; TOMKO, RACHEL LYNN	MEDICAL UNIVERSITY OF SOUTH CAROLINA	NATIONAL INSTITUTE ON DRUG ABUSE	2018 to 2025

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03729869

GET https://conductscience.org/api/trials/v1/NCT03729869/events?page=2

API reference For AI assistants